---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-028109"
form_type: "8-K"
ticker: "AURX"
cik: "0001091596"
company_name: "Nuo Therapeutics, Inc."
filed_at: "2026-08-17T11:55:11+00:00"
generated_at: "2026-08-17T12:03:01.130788+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nuo Therapeutics Q2 2026 revenue up >150% YoY; operating loss narrows to $167K

## Summary
- Q2 2026 total revenues ~$1.77M, up >150% YoY; H1 2026 revenues ~$3.07M, also up >150%.
- Q2 product revenues up 38% sequentially; Aurix brand up >30% sequentially.
- Q2 net operating loss ~$167K, improved ~$280K vs Q1 2026.
- Amended loan: interim funding $675K, $325K remaining under $2M commitments; option to increase borrowings Sept 30, 2026.
- Reimbursement fee milestone achieved under Smith+Nephew distribution agreement; payment expected this quarter.

## SEC filing metadata
- accession: 0001437749-26-028109
- form_type: 8-K
- ticker: AURX
- cik: 0001091596
- company_name: Nuo Therapeutics, Inc.
- filed_at: 2026-08-17T11:55:11+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1091596/000143774926028109/0001437749-26-028109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1091596/000143774926028109/aurx20260816c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-028109
- JSON: https://secwatch.observer/filing/0001437749-26-028109.json
- Plain text: https://secwatch.observer/filing/0001437749-26-028109.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.